INTRODUCTION
============

Lichen sclerosus (LS) is an uncommon mucocutaneous disorder that mainly affects females over a wide age range \[[@B1]\]. The lesion was first described as "*lichen planus atrophicus*" in 1887 by Hallopeau; five years later, Darrier described the same lesion as "*lichen planus sclerosus*", and, in 1940, Montogmery and Hill used the term "*lichen sclerosus et atrophicus*", which has been broadly used until recently. The term has changed to the contemporary "*lichen sclerosus*", since not all cases exhibit atrophy of the overlying epithelium \[[@B2]\]. The exact cause of this entity remains relatively obscure, and infectious, genetic, traumatic and autoimmune factors may participate in the pathogenesis \[[@B3]\].

LS is considered to be a chronic inflammatory disease affecting mainly the genital mucosa as well as the perianal region and the skin of the neck and the upper trunk \[[@B4]\]. The skin lesions are mainly characterised by flat, polygonal papules that form plaques. Genital lesions present clinically as atrophic plaques, purpuric lesions and dyspareunia in women, whereas phimosis and balanitis xerotica obliterans may occur in males \[[@B1]\]. Extragenital lesions have been reported in 15 - 20% of cases \[[@B3]\].

Although oral lesions are relatively rare, they can be the primary or the only manifestation of the disease \[[@B1]\]. Oral lesions are characterised by ivory or porcelain-white, round plaques. The main affected areas are the lips, buccal mucosa, and tongue and, less frequently, the gingivae and the anterior tonsillar pillar. The atrophic and sclerotic patches are commonly asymptomatic, although pruritus, soreness, burning, discomfort and tightening resulting in restriction of mouth opening have been reported. Telangiectasia may also be observed \[[@B4],[@B5]\]. Histopathological examination is required for the final diagnosis, as the condition cannot be readily distinguished on clinical grounds alone from lichen planus, leukoplakia and localised scleroderma \[[@B6]\]. LS treatment mainly consists of the use of topical corticosteroids, although therapy in asymptomatic cases is not mandatory \[[@B2]\].

Histopathologically, oral LS exhibits atrophic, and sometimes focally thickened, epithelium and subepithelial homogenization and hyalinization, with scarcity or loss of elastic fibres. There is a band-like subepithelial leukocytic inflammatory infiltrate that can move to the deeper portions of the lamina propria, following the maturation of the lesion \[[@B1]\].

The purpose of this study is to present a case of oral lichen sclerosus, diagnosed by utilising the histochemical Shikata's modified orcein stain, as well as a thorough review of all previously published oral lichen sclerosus cases in the English language literature.

CASE DESCRIPTION AND RESULTS
============================

Α 32-year-old Caucasian woman presented in an Oral Medicine Private Practice Clinic with white patches on the left upper lip on April 2012. The lesions were initially observed by the patient 3 months ago and were asymptomatic. She had been examined by her dermatologist with a clinical diagnosis of "lichen" or vitiligo. No cutaneous or genital lesions were noticed. No treatment of the oral lesions had been prescribed because of their asymptomatic nature. However, the patient considered that the lesions were cosmetically objectionable. Her medical history was non-contributory.

Clinical examination revealed asymptomatic white patches with irregular borders on the skin, the vermillion border and the mucosa of the left upper lip ([Figure 1](#fig1){ref-type="fig"}). In addition, erythematous areas were observed intermingled with the white lesions on the left labial mucosa ([Figure 2](#fig2){ref-type="fig"}).

![White plaque on the skin and the vermilion border of the left upper lip (x1/2).](jomr-09-e5-g001){#fig1}

![Intermingled white patches and erythematous areas on the mucosa of the upper lip (x1/2).](jomr-09-e5-g002){#fig2}

Under local anaesthesia, an incisional biopsy of the mucosal labial lesion was performed, taking a tissue specimen of 1.5 x 0.7 x 0.4 cm in dimension. Five μm thick formalin-fixed and paraffin-embedded tissue sections stained with hematoxylin and eosin were procceded for histopathological examination, which revealed an atrophic stratified squamous epithelium without rete pegs formation. The subepithelial connective tissue was dense, acellular, and hyalinized. Underneath the acellular zone, a moderate band-like lympohistiocytic inflammatory infiltrate was noticed ([Figures 3A - C](#fig3){ref-type="fig"}). Tissue sections of same thickness were further evaluated histochemically with Shikata's modified orcein stain (treated with acidified potassium permanganate, decolourized with 1% oxalic acid, and finally stained with Shikata orcein), which revealed distinctive scarcity or loss of elastin fibres in the hyalinized papillary lamina propria ([Figure 3D](#fig3){ref-type="fig"}). A final diagnosis of lichen sclerosus was rendered.

![A = histopathologic examination revealed epithelial atrophy, loss of rete pegs, hyalinization of the lamina propria and deep lymphohistiocytic inflammation (hematoxylin and eosin stain, original magnification x100).\
B = hyalinization and loss of cellularity of the subepithelial lamina propria (hematoxylin and eosin stain, original magnification x200).\
C = hyalinization and loss of cellularity of the subepithelial lamina propria (hematoxylin and eosin stain, original magnification x200).\
D = histochemical Shikata\'s modified orcein stain revealed loss of elastin fibres in the hyalinized subepithelial area (original magnification x100).\
E = normal deep connective tissue, stained with Shikata\'s modified orcein stain, showing plenty of brown-coloured elastin fibres in a perivascular orientation (original magnification x100).](jomr-09-e5-g003){#fig3}

Treatment consisted of topical application of fluocinonide 0.05% gel three times per day. Follow-up examination after 2 weeks revealed significant improvement of the lesions ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). The patient was placed on long-term follow-up course (3-monthly for 2 years and 6-monthly until now), without any recurrences noticed so far. The patient gave us her permission to use details of the case for publication.

![Resolution of the white plaque on the skin and vermillion border after treatment (x1/2).](jomr-09-e5-g004){#fig4}

![Intermingled white patches and erythematous areas on the mucosa of the upper lip (x1/2).](jomr-09-e5-g005){#fig5}

DISCUSSION
==========

LS is an unusual mucocutaneous disease that mainly affects the anogenital area and the skin. It mainly affects females with varying degrees of incidence (1 - 10:1) \[[@B1],[@B3],[@B4]\]. LS may affect patients of all ages, and in women there is a noticeable peak of occurrence in the second and fifth-sixth decades; men are mainly affected in the fourth-sixth decades, despite the fact that LS has been also described in boys with phimosis \[[@B2],[@B3],[@B4]\].

Oral manifestations of LS are rare and may appear with or without accompanying extraoral lesions \[[@B6]\]. A systematic review of the English language literature was conducted, using searching keywords: "oral lichen sclerosus", "oral white striae", "oral white patches", in MEDLINE, Web of Science, and Scopus databases, taking into consideration any case of histopathologically-assessed LS affecting the oral mucosa, with or without extraoral involvement. Since 1957, when Miller \[[@B8]\] published the first well-documented oral LS case, few cases without skin or genital involvement have been reported. Following data items of the reported oral LS cases were summarized in [Table 1](#T1){ref-type="table"}: "Author(s)", "Patient's sex/age", "Oral site(s)", "Oral symptoms", "Skin lesions", "Genital lesions", "Duration" (before clinical presentation), "Treatment". Attili and Attili \[[@B9]\] reported also 27 cases of LS of the lips; 20 out of them were the only manifestation of the disease. Our study adds one more case of LS that appeared solely in the oral cavity and perioral tissues, without further mucocutaneous involvement.

###### 

Summary of the reported oral LS cases in the English literature

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author(s)                    Patient\'s\                              Oral site(s)                               Oral\      Skin\     Genital\    Duration                  Treatment
                               age/sex                                                                             symptoms   lesions   lesions                               
  ---------------------------- ---------------------------------------- ------------------------------------------ ---------- --------- ----------- ------------------------- ---------------------------
  Sherlin et al. \[1\]         60/M                                     Gingival and buccal mucosa                 No         No        No          6 months                  No

                                                                                                                                                                              

  Louvain et al. \[2\]         70/F                                     Right buccal mucosa, tongue, gingiva       No         Yes       Yes         3 months                  Tacrolimus

                                                                                                                                                                              

  Azevedo et al. \[4\]         19/M                                     Buccal and labial mucosa                   No         No        No          8 months                  No

                                                                                                                                                                              

  34/F                         Upper lip and labial mucosa              Yes                                        No         No        3 months    Surgical excision         

                                                                                                                                                                              

  11/F                         Vermillion upper lip and labial mucosa   No                                         No         Yes       36 months   No                        

                                                                                                                                                                              

  38/F                         Buccal and labial mucosa                 Yes                                        Yes        No        20 days     Triamcinolone/\           
                                                                                                                                                    colchicine                

                                                                                                                                                                              

  31/F                         Lower labial mucosa and tongue           No                                         Yes        No        6 months    Surgical excision/\       
                                                                                                                                                    colchicines               

                                                                                                                                                                              

  28/F                         Tongue, buccal and labial mucosa         Yes                                        No         No        7 months    No                        

                                                                                                                                                                              

  Jensen et al. \[5\]          10/F                                     Buccal mucosa and sulcus                   No         No        NR          1 year                    No

                                                                                                                                                                              

  Jiménez et al. \[6\]         31/F                                     Gingiva, buccal sulcus and labial mucosa   No         Yes       No          2 years                   Triamcinolone

                                                                                                                                                                              

  Walsh et al. \[7\]           16/M                                     Vermilion upper lip, labial mucosa         No         Yes       No          9 months                  Methotrexate/prednisone

                                                                                                                                                                              

  Miller \[8\]                 48/F                                     Buccal mucosa                              No         Yes       Yes         7 months                  NR

                                                                                                                                                                              

  Kaur et al. \[10\]           16/M                                     Upper lip and gingiva                      Yes        Yes       No          1 year                    Prednisolone\
                                                                                                                                                                              and intralesional\
                                                                                                                                                                              triamcinolone

                                                                                                                                                                              

  Jiménez et al. \[11\]        19/F                                     Gingiva and frenulum of upper lip          Yes        No        No          NR                        Triamcinolone

                                                                                                                                                                              

  Brown et al. \[12\]          44/M                                     Soft palate                                No         No        No          NR                        No

                                                                                                                                                                              

  18/M                         Lower lip                                No                                         Yes        No        1 year      Clobetasol/testosterone   

                                                                                                                                                                              

  Chaudhry et al. \[13\]       60/F                                     Dorsum of the tongue                       Yes        Yes       Yes         4 years                   Benzydamine/betamethazone

                                                                                                                                                                              

  Mendonça et al. \[14\]       20/F                                     Vermilion lower lip, labial mucosa         No         No        No          NR                        No

                                                                                                                                                                              

  Buajeeb et al. \[15\]        22/F                                     Buccal mucosa, buccal sulcus\              Yes        No        No          NR                        Triamcinolone\
                                                                        vermilion lower lip and labial mucosa                                                                 and methylprednisolone

                                                                                                                                                                              

  Kim et al. \[22\]            7/F                                      Left lower lip and buccal mucosa           No         No        No          2 years                   Topical steroids/\
                                                                                                                                                                              pimecrolimus

                                                                                                                                                                              

  de Araujo et al. \[27\]      26/F                                     Upper labial mucosa, buccal sulcus\        NR         Yes       No          NR                        NR
                                                                        and gingiva                                                                                           

                                                                                                                                                                              

  Siar and Ng \[28\]           25/M                                     Buccal mucosa and lips                     Yes        Yes       No          6 months                  Triamcinolone

                                                                                                                                                                              

  Macleod and Soames\          57/F                                     Hard palate and tongue                     Yes        No        No          Several months            NR
  \[29\]                                                                                                                                                                      

                                                                                                                                                                              

  Schulten et al. \[30\]       59/F                                     Upper lip, left commissurae\               No         No        No          3 months                  No
                                                                        and tongue                                                                                            

                                                                                                                                                                              

  12/M                         Left lower lip                           No                                         No         No        9 months    Incisional biopsy         

                                                                                                                                                                              

  Rajlawat et al. \[31\]       14/F                                     Lower lip                                  No         No        No          1 year                    Clobetasone

                                                                                                                                                                              

  Kelly et al. \[32\]          10/F                                     Vermilion lower lip, labial mucosa         No         No        No          2 years                   Clobetasol

                                                                                                                                                                              

  Liu et al. \[33\]            54/F                                     Tongue dorsum                              No         No        No          10 days                   Tacrolimus

                                                                                                                                                                              

  58/F                         Tongue dorsum                            No                                         No         No        2 years     Tacrolimus                

                                                                                                                                                                              

  De Aquino Xavier\            47/M                                     Upper maxillary alveolar mucosa            No         No        No          NR                        Surgical excision
  et al. \[34\]                                                                                                                                                               

                                                                                                                                                                              

  George et al. \[35\]         20/M                                     Upper labial mucosa, adjacent\             NR         NR        NR          NR                        NR
                                                                        maxillary gingiva                                                                                     

                                                                                                                                                                              

  Tupsakhare et al. \[36\]     67/M                                     Soft palate                                No         No        No          11 years                  No

                                                                                                                                                                              

  Marangon Júnior et al.\      44/M                                     Upper lip                                  Yes        No        No          6 years                   No
  \[37\]                                                                                                                                                                      

                                                                                                                                                                              

  Wakamatsu et al. \[38\]      54/F                                     Lower lip                                  No         No        No          3 years                   Tacrolimus

                                                                                                                                                                              

  Ravits and Welsh \[39\]^a^   24/M                                     Buccal mucosa, gingiva and palate          NR         No        No          4 months                  Vit A

                                                                                                                                                                              

  42/M                         Buccal mucosa and palate                 NR                                         No         Yes       7 years     Vit A, Vit D2,\           
                                                                                                                                                    padothenyl alcohol        

                                                                                                                                                                              

  Sarkany \[40\]               57/F                                     Front of hard palate                       No         Yes       Yes         10 years                  NR

                                                                                                                                                                              

  Present case                 32/F                                     Upper lip, vermilion and labial mucosa     No         No        No          3 months                  Fluocinonide gel
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Ravits and Welsh \[39\] reported also a third case clinically suggestive of lichen sclerosus, but with no histopathological confirmation.

NR = not reported; M = male; F = female.

A wide range of ages has been recorded on the published cases with oral involvement, ranging from 7 up to 67 years. Most of them were females. Regarding localisation of the lesions, the lower and the upper lip, the buccal mucosa and the tongue were the most common areas of oral LS. The gingiva, the palate, and the anterior tonsillar pillar are also sites of involvement ([Table 1](#T1){ref-type="table"}) \[[@B1],[@B4]\].

Clinically, oral LS lesions appear as white papules that coalesce to form plaques. Striae and superficial erosions may also be observed; in such cases, LS may be indistinguishable from erosive lichen planus \[[@B10]\]. The lesions are mainly asymptomatic, although symptomatic cases of oral LS have been described ([Table 1](#T1){ref-type="table"}) \[[@B4]\]. Moreover, Jiménez et al. \[[@B11]\] observed loss of clinical periodontal attachment when the lesions were located on gingiva.

Histopathologically, the affected epithelium in oral LS exhibits similar features to those of lichen planus in various degrees (such as atrophy or hyperplasia and hydropic degeneration of basal cells) \[[@B6]\]. Generally, it is considered that skin lesions are mainly characterised by hyperplasia, whereas atrophic epithelium with loss of rete ridges is observed in mucosal lesions \[[@B5],[@B12]\]. However, the most important features, which are of diagnostic importance, are observed in the connective tissue. The papillary lamina propria is characterised by hyalinization and loss of cellularity \[[@B13],[@B14]\]. Special histochemical techniques, such as Verhoeff-Van Gieson or Shikata's modified orcein stain, show scarcity or loss of elastin fibres, a distinctive and diagnostic histopathological feature of LS \[[@B15]\]. Underneath the acellular area, a band-like lichenoid lymphocytic infiltrate, consisted of CD4+ and CD8+ T-cells is observed, and its location depends on the degree of maturation of the lesion; the more immature the lesion, the more superficial the infiltrate \[[@B4]\]. The histopathological examination is mandatory for confirmation of the diagnosis.

The ultrastructural findings of LS include the presence of broad diameter collagen fibres with loss of cross-striations, holes and gaps of the basal epithelial layer, increased number of Langerhan's cells and decreased number of melanocytes \[[@B3],[@B4],[@B16]\]. Immunofluorescent study is not diagnostically contributory, since it usually reveals only fibrinogen deposits at the basement membrane, equally to lichen planus \[[@B3],[@B15]\].

The differential diagnosis includes mainly localised scleroderma (morphea), lichen planus, leukoplakia, vitiligo, and oral submucous fibrosis \[[@B6],[@B10],[@B11]\]. Localised scleroderma can be easily excluded since it is not characterized by neither vacuolar degeneration of basal cells nor the lichenoid inflammatory reaction and loss of elastin fibres \[[@B15]\]. The immature lesions of LS, in which the lichenoid inflammation is more superficial, are quite difficult to be distinguished from lichen planus. This difficulty is easily overcome in more mature lesions, since in LS there is a thick hyalinization of the papillary lamina propria, similar to our case \[[@B14]\]. The same distinctive histopathological features are used in order to exclude leukoplakia and oral submucous fibrosis, along with the lack of dysplastic features in LS. Despite their decreased number, the presence of melanocytes (which are S-100 positive) in LS lesions is evident, excluding vitiligo \[[@B14]\]. Nonetheless, it should be noted that cases with co-existed lichen sclerosus, lichen planus and localised scleroderma have been reported to occur concurrently at the same patient \[[@B17]\].

The pathogenesis of LS remains obscure and several factors have been implicated. An immune-mediated disorder is the most plausible explanation \[[@B3]\]. There are studies that describe the co-existence of LS with autoimmunologic disorders, such as thyroiditis, diabetes mellitus, alopecia areata, pernicious anaemia or vitiligo \[[@B6]\]. Whether these entities share common pathogenetic mechanisms or its concurrence is an accidental finding is still unknown. Moreover, autoantibodies against the glycoprotein Extracellular Matrix Protein 1 (ECM1) have been detected in the serum of patients affected by LS \[[@B1]\].

ECM1 is a molecule that plays various roles; within the epithelium, it is correlated with the control of the keratinocyte differentiation, while it modulates the organisation of the connective tissue as one of the major binding partners to perlecan \[[@B1],[@B18]\]. Lipoid proteinosis, a rare metabolic disorder with uncommon oral manifestations similar to LS, is characterised by mutations in ECM1 gene \[[@B18]\]. Thus, it may be hypothesized that a dysfunction of ECM1 may produce the histopathological alterations that are observed in LS cases. Interleukin-6 (IL-6) has also been suggested to play an important role in the pathogenesis of LS, since an increased amount of this cytokine was detected in the atrophic epithelium of LS cases \[[@B3]\].

Furthermore, there are studies that suggest a genetic predisposition. LS has been observed within members of the same family (familial LS) or in identical twins \[[@B3],[@B19]\]. There is no specific association of LS with HLA antigens, though studies suggest a possible correlation with HLA-DQ7 alleles \[[@B20]\]. The possible connection of LS with particular microbial infections, especially by *Borrelia burgdorferi*, has also been mentioned, as 60% of LS specimens revealed superficial *Borrelia* colonisation \[[@B4]\]. In many cases, significant clinical improvement was noticed after antibiotic treatment. Viral infections, especially by HPV, have been reported to cause or contribute to the development of LS lesions, especially in genitalia; this correlation though remains questionable \[[@B21]\]. Finally, local irritation or traumas have been linked to the pathogenesis of LS, especially for cutaneous and genital lesions. In these cases, the Köebner phenomenon (occurrence of LS in areas of already damaged skin or mucosa) has been suggested as the potential pathway \[[@B3]\].

Until now, there is no specific successful treatment for the oral manifestation of LS. Treatment is commonly provided in cases of LS with soreness and discomfort or in cases that cosmetic concerns have arisen. Due to the proposed immune-mediated pathogenesis of LS, along with the inflammatory component observed clinically and microscopically, the most commonly used treatment modalities involve topical application or intralesional injections of corticosteroids and topical calcineurin inhibitors (tacrolimus, pimecrolimus); cryotherapy, and surgical excision for small lesions have also been utilised ([Table 1](#T1){ref-type="table"}) \[[@B1],[@B2],[@B22]\]. Colchicine, a drug that is mainly used in other mucocutaeous diseases, like Behçet's syndrome, psoriasis and scleroderma, has also been used in a limited number of LS cases \[[@B4]\]. For the genital manifestations, topical application of testosterone, narrow-band UVB and psoralen UVA (PUVA) are proposed to be effective in reduction of the lesions following one or more courses \[[@B23],[@B24]\].

In the literature, no malignant transformation of oral LS cases has been reported. Nevertheless, genital LS lesions have been associated with a 3 - 5% relative risk for the development of squamous cell carcinoma \[[@B3]\]. Since oral LS may be accompanied by genital lesions, it is highly recommended that the patient should undergo a thorough clinical examination and be placed in a long-term follow-up course \[[@B24]\].

CONCLUSIONS
===========

The pertinent English language literature review has revealed a few cases of oral lichen sclerosus \[[@B1],[@B2],[@B4],[@B22],[@B27]\]. Although considerably uncommon, oral manifestations of lichen sclerosus should be included in the clinical differential diagnosis of white patches of the oral mucosa and the vermillion border of the lips. Further histopathological evaluation of the specimen with Shikata's modified orcein stain is useful for rendering a proper diagnosis.
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